Galapagos NV (GLPG)
27.13
+1.91
(+7.57%)
USD |
NASDAQ |
Nov 22, 16:00
27.12
-0.02
(-0.06%)
After-Hours: 20:00
Galapagos Profit Margin (Quarterly): -84.26% for Sept. 30, 2024
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -84.26% |
| June 30, 2024 | 11.54% |
| March 31, 2024 | |
| December 31, 2023 | |
| September 30, 2023 | 42.24% |
| June 30, 2023 | 8.49% |
| March 31, 2023 | 39.62% |
| December 31, 2022 | |
| September 30, 2022 | 15.82% |
| June 30, 2022 | -13.83% |
| March 31, 2022 | -9.76% |
| December 31, 2021 | -19.59% |
| September 30, 2021 | -100.7% |
| June 30, 2021 | -46.02% |
| March 31, 2021 | 8.22% |
| December 31, 2020 | -37.08% |
| September 30, 2020 | -64.23% |
| June 30, 2020 | -115.5% |
| March 31, 2020 | -53.37% |
| December 31, 2019 | -105.8% |
| September 30, 2019 | 56.98% |
| Date | Value |
|---|---|
| June 30, 2019 | -80.44% |
| March 31, 2019 | -147.2% |
| December 31, 2018 | 15.55% |
| September 30, 2018 | 15.64% |
| June 30, 2018 | -43.83% |
| March 31, 2018 | -98.35% |
| December 31, 2017 | -76.11% |
| September 30, 2017 | -135.9% |
| June 30, 2017 | -132.3% |
| March 31, 2017 | -40.02% |
| December 31, 2016 | 57.79% |
| September 30, 2016 | -215.5% |
| June 30, 2016 | -12.98% |
| March 31, 2016 | |
| December 31, 2015 | -792.7% |
| September 30, 2015 | -477.2% |
| June 30, 2015 | -168.1% |
| March 31, 2015 | -96.14% |
| December 31, 2014 | -50.86% |
| September 30, 2014 | -90.42% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-115.5%
Minimum
Jun 2020
42.24%
Maximum
Sep 2023
-30.83%
Average
-19.59%
Median
Dec 2021
Profit Margin (Quarterly) Benchmarks
| UCB SA | -- |
| Mithra Pharmaceuticals SA | -- |
| Nyxoah SA | -1.35K% |
| Celyad Oncology SA | -- |
| MDxHealth SA | -47.99% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | 7.25% |
| Return on Assets | 4.72% |
| Return on Invested Capital | 7.25% |
| Gross Profit Margin (Quarterly) | 99.97% |
| Operating Margin (Quarterly) | -90.74% |
| Return on Net Operating Assets | 38.91% |